LONDON (dpa-AFX) - Alexion has received European Union approval for Koselugo (selumetinib), an oral and selective MEK inhibitor. The approval covers the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients diagnosed with neurofibromatosis type 1 (NF1), AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said in a statement on Tuesday.
Koselugo has been recently approved in Japan and other countries for the treatment of adult patients with NF1 who have symptomatic, inoperable plexiform neurofibromas based on data from the KOMET Phase III trial, and additional regulatory reviews are ongoing.
neurofibromatosis type 1 is a rare, progressive, genetic condition usually diagnosed in early childhood, but often progressing into adulthood, that can impact every organ system.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
